Introduction: Dyslipidemia (DL) is a principal risk factor in the pathophysiology of cardiovascular diseases (CVD) and diabetes mellitus (DM). It may correlate with Medoroga, which is a risk factor for diseases like Prameha, Hridroga Jwara, Bhagandara, Vrana, Vataroga, etc. Aim: To assess the clinical efficacy of Vyoshadi Guggulu (VG) and Haritaki Churna (HC) in the management of DL and changes in the quality of life of the study participants. Materials and methods: It was a prospective, multicenter, single-arm study. The Ayurvedic formulations VG (2 tablets of 500 mg each TDS) after food with lukewarm water and HC (3 gm bd) were administered for 12 weeks with a follow-up of 2 weeks without interventions. Totally, 146 participants belonging to either sex, 18 to 70 years with low-density lipoprotein (LDL) 100 to 160 mg/dL and/or serum cholesterol 200 to 250 mg/dL and/or serum triglycerides (TG) 150 to 250 mg/dL and those willing and able to participate were included in the study. The outcome measures were changes in lipid profile, clinical safety, and changes in the quality of life. Results: There was a significant reduction (p < 0.005) in the mean serum cholesterol level, i.e., 214.8 reduced to 208.3 after 84 days of treatment and (p < 0.001) in the mean high-density lipoprotein (HDL), i.e., 46.3 reduced to 44.04 after 84 days of treatment. There was no significant change in the serum TG, LDL, and very-low density lipoprotein (VLDL) value. There is also improvement in the quality of life (p < 0.001) of the participants. There are no significant changes observed in the laboratory safety parameters. This corroborated that drugs are safe to use. Conclusion: Vyoshadi Guggulu and Haritaki Churna are effective in the management of DL and are safe to use. Clinical significance: The use of these drugs may lower the complications of DL.